POLESTAR Trial (WCLC 2024): Aumolertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC скачать в хорошем качестве

POLESTAR Trial (WCLC 2024): Aumolertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC

Explore the interim results from the Phase III POLESTAR trial, presented as Abstract PL04.13 by Meng X, Ge H, Ning F, et al., evaluating the efficacy of aumolertinib as consolidation therapy following chemoradiotherapy in patients with unresectable Stage III EGFR-mutant non-small cell lung cancer (NSCLC). This study represents a major advancement in targeted post-CRT therapy, building on the momentum of trials like LAURA, but with aumolertinib, a next-generation EGFR TKI. 📌 Why it matters: Could aumolertinib become a new standard in the consolidation setting for EGFR+ LA-NSCLC? 👍 Like this video if you find it helpful 🔁 Share with colleagues and fellow oncology professionals 💬 Comment below with your thoughts on targeted therapy in Stage III NSCLC ✅ Subscribe for more updates from WCLC, ASCO, ESMO, and NEJM 🔔 Hit the bell so you never miss a major clinical trial update #POLESTARTrial #WCLC2024 #Aumolertinib #EGFR #NSCLC #LungCancer #RadiationOncology #TargetedTherapy #StageIIILungCancer #ClinicalTrials #OncologyNews